Promising leukemia combo trial halted early – what we know

NCT ID NCT04240002

First seen Jan 09, 2026 · Last updated May 06, 2026 · Updated 17 times

Summary

This study tested a drug called gilteritinib, which targets a specific genetic change (FLT3/ITD) in acute myeloid leukemia (AML), combined with standard chemotherapy. It included children, teens, and young adults whose leukemia had come back or didn't respond to treatment. The goal was to find the best dose and see how many patients achieved remission. The study was stopped early after enrolling only 9 participants, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • SIte IT39001

    Roma, 165, Italy

  • Site DE49004

    Essen, North Rhine-Westphalia, 45147, Germany

  • Site ES34001

    Barcelona, 08950, Spain

  • Site GB44001

    Birmingham, B4 6NH, United Kingdom

  • Site GB44005

    Cardiff, CF14 4XW, United Kingdom

  • Site UK44007

    Sutton, United Kingdom

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38105, United States

Conditions

Explore the condition pages connected to this study.